These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 21855308)

  • 1. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal or inducible nitric oxide synthase (NOS) expression level is not involved in the different susceptibility to nigro-striatal dopaminergic neurotoxicity induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) between C57BL/6 and BALB/c mice.
    Ito T; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):121-5. PubMed ID: 21788124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B.
    Rodríguez S; Ito T; He XJ; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):127-33. PubMed ID: 21795029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neuroblastic apoptosis in the subventricular zone is caused by 1-methy-4-phenylpiridinium (MPP(+)) converted from MPTP through MAO-B.
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2012 Nov; 64(7-8):761-5. PubMed ID: 21324658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
    Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
    Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary administration of paraquat for 13 weeks does not result in a loss of dopaminergic neurons in the substantia nigra of C57BL/6J mice.
    Minnema DJ; Travis KZ; Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck MJ; Mathews JM; Tisdel MO; Cook AR; Botham PA; Smith LL
    Regul Toxicol Pharmacol; 2014 Mar; 68(2):250-8. PubMed ID: 24389362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration.
    Choi DY; Lee MK; Hong JT
    Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.
    Saporito MS; Brown EM; Miller MS; Carswell S
    J Pharmacol Exp Ther; 1999 Feb; 288(2):421-7. PubMed ID: 9918541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A; Fascetti F; Corsini GU; Piccardi MP
    Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
    Muralikrishnan D; Samantaray S; Mohanakumar KP
    Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
    Kreisler A; Gelé P; Wiart JF; Lhermitte M; Destée A; Bordet R
    Brain Res; 2007 Mar; 1135(1):77-84. PubMed ID: 17196944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins.
    Nagel F; Bähr M; Dietz GP
    Brain Res Bull; 2009 Jun; 79(5):303-9. PubMed ID: 19406215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-lasting reactive changes observed in microglia in the striatal and substantia nigral of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Yasuda Y; Shinagawa R; Yamada M; Mori T; Tateishi N; Fujita S
    Brain Res; 2007 Mar; 1138():196-202. PubMed ID: 17275793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secalonic acid A protects dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP⁺)-induced cell death via the mitochondrial apoptotic pathway.
    Zhai A; Zhu X; Wang X; Chen R; Wang H
    Eur J Pharmacol; 2013 Aug; 713(1-3):58-67. PubMed ID: 23665112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
    Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
    Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Effects of MPTP and Paraquat on Dopaminergic Neurons and Microglia in the Substantia Nigra Pars Compacta of C57BL/6 Mice.
    Smeyne RJ; Breckenridge CB; Beck M; Jiao Y; Butt MT; Wolf JC; Zadory D; Minnema DJ; Sturgess NC; Travis KZ; Cook AR; Smith LL; Botham PA
    PLoS One; 2016; 11(10):e0164094. PubMed ID: 27788145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
    Fornai F; Alessandrì MG; Torracca MT; Bassi L; Corsini GU
    J Pharmacol Exp Ther; 1997 Oct; 283(1):100-7. PubMed ID: 9336313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute toxicity of MPTP and MPP(+) in the brain of embryo and newborn mice.
    Sai T; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):113-9. PubMed ID: 21798732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.